openPR Logo
Press release

Dr. Axel Ullrich, Director at the Max Planck Institute of Biochemistry, Martinsried chooses Proteros as preferred service partner for kinase drug discovery

02-21-2011 10:55 AM CET | Science & Education

Press release from: Proteros biostructures GmbH

/ PR Agency: BCNP Consultants GmbH
Martinsried, Germany, February 21, 2011. Proteros Biostructures GmbH (“Proteros”) and Max Planck Institute (“MPI”) of Biochemistry, Martinsried announced today that Dr. Axel Ullrich has chosen Proteros as the preferred service partner to support kinase drug discovery research at the Department of Molecular Biology.

Proteros will develop kinase-focused assay systems and provide screening services employing its proprietary platform for screening to support the validation of novel kinase targets for drug discovery.

Dr. Axel Ullrich, co-founder of four drug discovery companies and key researcher in the development of two successfully marketed kinase drugs said that he has chosen Proteros as preferred partner for his continued drug discovery projects. Dr. Ullrich stated that he has successfully cooperated with Proteros on several projects during the past few years and is pleased with Proteros’ performance. Moreover he stated, “Proteros has proven to be a reliable and flexible partner with expertise in characterizing compound-target interactions and in the development of biochemical and cellular assay technologies.”

About Proteros:
Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery within life sciences. The company accelerates and improves protein structure analysis, kinetic and thermodynamic compound-target interaction studies and structure-guided drug discovery with its expertise, industrialized processes and unique technologies for crystallography, screening, and fragment-based lead generation. Proteros currently provides services for more than 80 pharmaceutical and biotechnology clients in Europe, North America and Japan.

About Dr. Axel Ullrich:
Dr. Ullrich is one of the leading cancer and kinase experts worldwide and among the 10 most cited scientists over the past 30 years. Dr. Ullrich is co-founder of the companies SUGEN, Axxima Pharmaceuticals, U3 Pharma and Kinaxo. His research resulted in the development of anti cancer drugs as Herceptin® and SUTENT®. Dr. Ullrich today is Director of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Martinsried.

Contact:
Proteros biostructures GmbH
Kurt Herrenknecht, Ph.D.
Am Klopferspitz 19
82152 Martinsried
Germany
Phone: +49 (0) 89 7007 61 – 0
E-Mail: herrenknecht@proteros.com
Internet: www.proteros.com

Dr. Axel Ullrich
Max-Planck-Institute of Biochemistry
Am Klopferspitz 18a
82152 Martinsried
Germany
Phone: +49 (0) 89 8578 2513
E-Mail: ullrich@biochem.mpg.de

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dr. Axel Ullrich, Director at the Max Planck Institute of Biochemistry, Martinsried chooses Proteros as preferred service partner for kinase drug discovery here

News-ID: 163314 • Views:

More Releases from Proteros biostructures GmbH

PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company. The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology. Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas. At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services. Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and

All 4 Releases


More Releases for Ullrich

Extruded Aluminum Tubing Market Riding the Wave: Market Players Exploiting Growt …
"This comprehensive Extruded Aluminum Tubing report offers a deep dive into the global market, encompassing a wide spectrum of analyses to equip you with a profound understanding of its dynamics. Beyond the standard SWOT analysis, our study incorporates a diverse range of analytical approaches, including the insightful PESTLE analysis, qualitative and quantitative assessments, absolute dollar opportunity analysis, and the robust Porter's Five Forces analysis. We leave no stone unturned when
Global Mobile Ladder Market Reaching New Heights in Safety and Accessibility 203 …
"Mobile Ladder Market" report's each segment and sub-segment is analyzed in detail so that no stone is left unturned in ensuring that the customer receives the top-quality information about the Mobile Ladder Market by Infinity Business Insights. This report will help the viewer in Better Decision Making. With a CAGR of 8.5% from 2023 to 2030, the global mobile ladder market is anticipated to reach an estimated USD 2.9 billion by
Global Mobile Ladder Market research report provides an in-depth analysis of the …
The research, titled "Mobile Ladder Market," covers all significant market factors, including market size, share, growth rate, revenue trends, corporate developments, and new investment prospects. Insightful data for company strategies, regional and national growth categories, and industry valuation based on top key player analysis are all described in the Mobile Ladder market research. The paper elaborates historical and future trends, current events, the cost structure of manufacturing, supply and demand
Extruded Seamless Aluminum Tubing Market to Witness Huge Growth by Key Players: …
ReportsnReports publishes the report titled Extruded Seamless Aluminum Tubing that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes the report a valuable asset for stakeholders to make robust decisions. This report also provides an in-depth overview of product type, specification, technology, and production analysis considering vital factors
Amit Gupta passes the baton to Ullrich Loeffler as CEO of Ecosystm
31 March 2022, SINGAPORE: Ecosystm, the disruptive technology research and advisory company today announced the transition of Co-founder and Chief Operating Officer Ullrich Loeffler to the role of Chief Executive Officer. As the group continues its ambitious innovation strategy, Amit Gupta will step into the role of Founder and Chairman. Ecosystm has seen exponential growth since the company launched in 2018 and has been challenging traditional technology research firms since its
Extruded Aluminum Tubing Market 2019 – 2025 with Major Industries like – Ull …
"Extruded Aluminum Tubing Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. Get Exclusive FREE Sample Copy Of this Report @ https://www.upmarketresearch.com/home/requested_sample/24578 UpMarketResearch offers a latest published report on “Global Extruded Aluminum Tubing Market Analysis and Forecast 2019 - 2026” delivering key insights and providing a competitive